



HAL
open science

Ulceroglandular Infection and Bacteremia Caused by *Francisella salinarina* in Immunocompromised Patient, France

Aurélie Hennebique, Yvan Caspar, Max Maurin, Sandrine Boisset, Isabelle Pelloux, Maria Pilar Gallego-Hernanz, Christophe Burucoa, France Cazenave-Roblot, Chloé Plouzeau, Blandine Rammaert

► To cite this version:

Aurélie Hennebique, Yvan Caspar, Max Maurin, Sandrine Boisset, Isabelle Pelloux, et al.. Ulceroglandular Infection and Bacteremia Caused by *Francisella salinarina* in Immunocompromised Patient, France. *Emerging Infectious Diseases*, 2022, 28 (2), pp.465-467. 10.3201/eid2802.211380 . hal-03549298

HAL Id: hal-03549298

<https://hal.science/hal-03549298>

Submitted on 31 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

2. Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. *eLife*. 2021;10:10. <https://doi.org/10.7554/eLife.69336>
3. Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunkskaya A, et al. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. *Sci Rep*. 2021;11:12930. <https://doi.org/10.1038/s41598-021-92206-y>
4. Zurochka A, Dobrinina M, Zurochka V, Hu D, Solovyev A, Ryabova L, et al. Seroprevalence of SARS-CoV-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: the results of the single-center, prospective, cross-sectional study. *Vaccines (Basel)*. 2021;9:627. <https://doi.org/10.3390/vaccines9060627>
5. Cook S, Malyutina S, Kudryavtsev A, et al. Know Your Heart: rationale, design and conduct of a cross-sectional study of cardiovascular structure, function, and risk factors in 4,500 men and women aged 35–69 years from two Russian cities, 2015–18. *Wellcome Open Research* 2018;3:67. <https://doi.org/10.12688/wellcomeopenres.14619.3>
6. Kuvshinova IN, Nekrasov BG, Livitskaya NI, Molodykh SV, Rukavishnikov M. Sensitivity and specificity of reagent kits of JSC “Vector-Best” for the detection of immunoglobulins of different classes to SARS-CoV-2 [in Russian]. *Spravochnik Zaveduyushchego KDL*. 2021;10:27–32.
7. Barchuk A, Shirokov D, Sergeeva M, Tursunzade R, Dudkina O, Tychkova V, et al. Evaluation of the performance of SARS-CoV-2 antibody assays for a longitudinal population-based study of COVID-19 spread in St. Petersburg, Russia. *J Med Virol*. 2021;93:5846–52. <https://doi.org/10.1002/jmv.27126>
8. Sempos CT, Tian L. Adjusting coronavirus prevalence estimates for laboratory test kit error. *Am J Epidemiol*. 2021;190:109–15. <https://doi.org/10.1093/aje/kwaa174>
9. Government of Russia. The number of people vaccinated against coronavirus in Arkhangelsk [in Russian]. 2021 [cited 2021 Sep 20]. <https://gogov.ru/covid-v-stats/arkhangelsk>
10. European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA, 14 June 2021. 2021 [cited 2021 Sep 20]. <https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans>

Address for correspondence: David Leon, London School of Hygiene & Tropical Medicine, Keppel St, London, WC1E 7HT, UK; email: david.leon@lshtm.ac.uk

Ulceroglandular Infection and Bacteremia Caused by *Francisella salimarina* in Immunocompromised Patient, France

Aurélie Hennebique,¹ Yvan Caspar,¹ Max Maurin, Sandrine Boisset, Isabelle Pelloux, Maria Pilar Gallego-Hernanz, Christophe Burucoa, France Cazenave-Roblot, Chloé Plouzeau, Blandine Rammaert

Author affiliations: Université Grenoble Alpes, Grenoble (A. Hennebique, Y. Caspar, M. Maurin, S. Boisset); CHU Grenoble Alpes, Grenoble, France (A. Hennebique, Y. Caspar, M. Maurin, S. Boisset, I. Pelloux); CHU de Poitiers, Poitiers, France (M.P. Gallego-Hernanz, C. Burucoa, F. Cazenave-Roblot, C. Plouzeau, B. Rammaert); Université de Poitiers, Poitiers (C. Burucoa, F. Cazenave-Roblot, B. Rammaert)

DOI: <https://doi.org/10.3201/eid2802.211380>

Although *Francisella tularensis* is a well-known, highly virulent bacterium that causes tularemia in humans, other *Francisella* species have been associated with sporadic human infections. We describe a human cutaneous infection with bacteremia caused by *F. salimarina*, a *Francisella* species recently identified from seawater and fishes, in an immunocompromised patient in France.

Although the taxonomy of the genus *Francisella* includes a wide diversity of species, only *F. tularensis* subspecies *tularensis* and *F. tularensis* subsp. *holarctica* cause the potentially life-threatening disease tularemia (1). Several *Francisella* spp., including *F. philomiragia*, *F. novicida*, *F. opportunistica*, and *F. hispaniensis*, are occasional opportunistic human pathogens; the other *Francisella* spp. are not associated with human infections (1). We describe a human infection caused by *F. salimarina*, recently identified from aquatic environments and fishes.

In June 2017, a 76-year-old man received a diagnosis of acute myelomonocytic leukemia and was admitted to Poitiers University Hospital (Poitiers, France). The patient lived in a small town 30 km from the Atlantic Ocean, had not travelled abroad recently, and had no pets. The day after admission, first-line chemotherapy of subcutaneous azacitidine was started for 7 days. After 3 days of chemotherapy, piperacillin/tazobactam was introduced for 5 days because of febrile aplasia. The patient was then discharged with

¹These authors contributed equally to this article.

an antibiotic prophylaxis (sulfamethoxazole/trimethoprim at 800 mg/160 mg 3×/wk). On July 26, the second azacitidine treatment was not administered because the patient again experienced febrile aplasia. Physical examination revealed skin lesions on 2 left-hand fingers that had appeared 3 weeks earlier. These lesions were erythematous and crusty but not purulent (Figure, panel A). They were associated with a left axillary lymphadenopathy. Antibiotic treatment with piperacillin/tazobactam and teicoplanin was started but was changed to imipenem/cilastatin and daptomycin after 5 days because of poor clinical response. Aerobic blood cultures performed at admission tested positive on July 31 and Gram stain showed a small gram-negative coccobacillus (Figure, panel B). Antibiotic treatment was changed to cefepime, administered for 3 days. No identification could be obtained by MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry (Vitek MS; bioMérieux, <https://www.biomerieux.com>). The strain was identified as a *Francisella* spp. by 16S rDNA amplification and sequencing. A cutaneous biopsy was performed because of persistent fever and worsening skin lesions in the patient; the same *Francisella* spp. strain was isolated. Doxycycline (100 mg 2×/d) was administered for 8 days, followed by sulfamethoxazole/trimethoprim, which led to apyrexia.

The *Francisella* spp. strain (referred to as CHUGA-F75) was sent to the French National Reference Centre for *Francisella* for further characterization. The strain was strictly aerobic and grew well on chocolate agar supplemented with IsoVitaleX (bioMérieux), blood agar, and tryptic soy agar, yielding gray mucoid colonies after 24 h of incubation at 35°C in 5% CO₂, but not on Drigalski agar (Figure, panels C, D). Biochemical testing revealed a positive oxidase, a weakly positive catalase, and a negative urease test. The strain was also halotolerant; it could grow in modified Mueller-Hinton broth with up to 8% NaCl. ISFtu2, Tul4, and type

B real-time PCR tests, which detected most *Francisella* spp., *F. tularensis*, and *F. tularensis* subsp. *holarctica*, were all negative for DNA extracted from this strain (2,3). Species identification could not be obtained by using MALDI-TOF mass spectrometry, either with the routine database (MBT IVD Library DB-7171), the Biotox database (MBT SR Library; both from Bruker, <https://www.bruker.com>), or the French National Reference Centre for *Francisella* database containing *F. tularensis*, *F. novicida*, and *F. philomiragia* (4). Therefore, we performed whole-genome sequencing by using second and third next-generation sequencing platforms MiSeq (Illumina, <https://www.illumina.com>) and MinION (Oxford Nanopore Technologies, <https://nanoporetech.com>). Hybrid assembly of the sequencing data using Unicycler software on the Galaxy web platform (<https://usegalaxy.org>) enabled circularization of a 1,940,863 bp bacterial chromosome (Genbank accession no. CP076680). Whole-genome-based identification of the strain was assessed by using the Type Strain Genome Server (<https://tygs.dsmz.de>) (5). The CHUGA-F75 strain clustered in the same branch as the *F. salinarina* SYSU SYW-1, the *F. marina* E95-16, and the *F. salina* TX07-7308 strains (Appendix Figure, <https://wwwnc.cdc.gov/EID/article/28/2/21-1380-App1.pdf>), probably representing the same species because of high genetic homology, although different species names have been published (6–8). Digital DNA-DNA hybridization >70%, average nucleotide identity >95%, and difference in percent guanine-cytosine content <1 percent between the CHUGA-F75 strain and the 3 *F. salinarina*, *F. marina*, and *F. salina* strains confirmed the CHUGA-F75 isolate belonged to the same species. Because the only validly published species name according to the International Code of Nomenclature of prokaryotes is *F. salinarina*, we identified CHUGA-F75 as *F. salinarina*. Using the broth microdilution method in cation-adjusted Mueller-Hinton broth as recommended by the Clinical and Laboratory Standards




Figure. Skin ulcers and bacteremia caused by *Francisella salinarina* in an immunocompromised patient and isolated bacteria morphology, France. A) Skin lesion on 2 left-hand fingers. B) Small gram-negative coccobacillus isolated from blood and skin lesions (original magnification ×1,000). C) Growth on blood agar after 2 days of incubation at 35°C in 5% CO₂. D) Growth on chocolate agar after 2 days of incubation at 35°C in 5% CO₂.

Institute, we found that the CHUGA-F75 strain was sensitive to gentamicin (MIC = 0.125 mg/L), doxycycline (MIC = 1 mg/L), and ciprofloxacin (MIC = 0.016 mg/L) and resistant to sulfamethoxazole/trimethoprim (MIC = 32 mg/L).

F. marina was described as responsible for systemic disease in fishes (*Lutjanus guttatus*, the cultured spotted rose snapper) in Central America, whereas 4 *F. salinarum* strains have been isolated from coastal seawater in Guangdong Province, China, and 1 strain of *F. salina* has been grown from brackish seawater and seaweed off the coast of Galveston, Texas, USA (6–8). To our knowledge, these *Francisella* spp. were not responsible for human infection so far. This report, like previous descriptions of human infections caused by emergent *Francisella* spp., highlights that environmental or fish-related *Francisella* spp. could be responsible for opportunistic human infections resembling tularemia.

The Direction Générale de l'Armement of France funded this research (ANR-17-ASTR-0024).

About the Author

Dr. Hennebique is a clinical microbiologist in the bacteriology laboratory of Grenoble University Hospital, Grenoble, France, which also hosts the French National Reference Center for *Francisella tularensis*. Her primary research interests are the tularemia agent, with an emphasis on its mechanisms of environmental survival in water, susceptibility to antibiotics, and virulence.

References

- Hennebique A, Boisset S, Maurin M. Tularemia as a waterborne disease: a review. *Emerg Microbes Infect.* 2019; 8:1027–42. <https://doi.org/10.1080/22221751.2019.1638734>
- Versage JL, Severin DDM, Chu MC, Petersen JM. Development of a multitarget real-time TaqMan PCR assay for enhanced detection of *Francisella tularensis* in complex specimens. *J Clin Microbiol.* 2003;41:5492–9. <https://doi.org/10.1128/JCM.41.12.5492-5499.2003>
- Kugeler KJ, Pappert R, Zhou Y, Petersen JM. Real-time PCR for *Francisella tularensis* types A and B. *Emerg Infect Dis.* 2006;12:1799–801. <https://doi.org/10.3201/eid1211.060629>
- Regoui S, Hennebique A, Girard T, Boisset S, Caspar Y, Maurin M. Optimized MALDI TOF mass spectrometry identification of *Francisella tularensis* subsp. *holarctica*. *Microorganisms.* 2020;8:E1143. <https://doi.org/10.3390/microorganisms8081143>
- Meier-Kolthoff JP, Göker M. TYGS is an automated high-throughput platform for state-of-the-art genome-based taxonomy. *Nat Commun.* 2019;10:2182. <https://doi.org/10.1038/s41467-019-10210-3>
- Challacombe JF, Petersen JM, Gallegos-Graves LV, Hodge D, Pillai S, Kuske CR. Whole-genome relationships among *Francisella* bacteria of diverse origins define new species and provide specific regions for detection. *Appl Environ Microbiol.* 2017;83:e02589-16.
- Li L-H, Luo H-M, Feng J-H, Ming Y-Z, Zheng M-L, Deng G-Y, et al. *Francisella salinarum* sp. nov., isolated from coastal seawater. *Int J Syst Evol Microbiol.* 2020;70:3264–72. <https://doi.org/10.1099/ijsem.0.004164>
- Soto E, Griffin MJ, Morales JA, Calvo EB, de Alexandre Sebastião F, Porras AL, et al. *Francisella marina* sp. nov., etiologic agent of systemic disease in cultured Spotted Rose Snapper (*Lutjanus guttatus*) in Central America. *Appl Environ Microbiol.* 2018;84:e00144-18. <https://doi.org/10.1128/AEM.00144-18>

Address for correspondence: Aurélie Hennebique, Service de Bactériologie-Hygiène Hospitalière, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, CS10217, 38043 Grenoble CEDEX 9, France; email: ahennebique@chu-grenoble.fr

Surveillance of Rodent Pests for SARS-CoV-2 and Other Coronaviruses, Hong Kong

Elliott F. Miot,¹ Brian M. Worthington,¹ Kar Hon Ng,¹ Lucy de Guilhem de Lataillade,¹ Mac P. Pierce, Yunshi Liao, Ronald Ko, Marcus H. Shum, William Y. Cheung, Edward C. Holmes, Kathy S. Leung, Huachen Zhu, Leo L. Poon, J.S. Malik Peiris, Yi Guan, Gabriel M. Leung, Joseph T. Wu, Tommy T. Lam

DOI: <https://doi.org/10.3201/eid2802.211586>

Author affiliations: University of Hong Kong State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (E.F. Miot, B.M. Worthington, K.H. Ng, L. de Guilhem de Lataillade, M.P. Pierce, Y. Liao, M.H. Shum, W.Y. Cheung, H. Zhu, Y. Guan, T.T. Lam); University of Hong Kong School of Public Health, Hong Kong (E.F. Miot, B.M. Worthington, K.H. Ng, L. de Guilhem de Lataillade, M.P. Pierce, Y. Liao, R. Ko, M.H. Shum, W.Y. Cheung, H. Zhu, L.L. Poon, M.J. Peiris, Y. Guan, G.M. Leung, J.T. Wu, T.T. Lam); University of Hong Kong HKU-Pasteur Research Pole, Hong Kong (E.F. Miot, L. de Guilhem de Lataillade, L.L. Poon, J.S.M. Peiris); Centre for Immunology & Infection Limited, Hong Kong (E.F. Miot, L. de Guilhem de Lataillade, L.L. Poon,

¹These coauthors contributed equally to this article.